CAPS

Business Context and Reporting Period

Company: OrthoLogic Corp. (operating as Capstone Therapeutics)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: A development-stage biotechnology company focused on two therapeutic peptide platforms: AZX100 (for dermal scarring, pulmonary disease, and vascular applications) and Chrysalin (for tissue repair and vascular applications). The company sold its revenue-generating bone device business in 2003 and currently has no product revenue.

Key Financial Metrics

Note: The company has no revenue. Operating expenses consist primarily of Research and Development ($2.8M for Q3; $7.8M for YTD) and General and Administrative costs ($0.8M for Q3; $2.4M for YTD).

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the nine months ended September 30, 2008, increased to $8.6 million from $7.7 million in the same period in 2007. This was driven by increased R&D costs for Phase 1 clinical trials in dermal scarring and reduced interest income due to lower rates and reduced investment balances.
• Expense Trends: General and Administrative expenses decreased by $419,000 year-over-year due to cost containment. Research and Development expenses increased by $406,000 year-over-year.
• Liquidity Position: Cash and cash equivalents decreased significantly from $20.9 million at December 31, 2007, to $7.2 million at September 30, 2008. However, short-term investments increased from $18.2 million to $39.3 million.
• Stock Repurchases: The company repurchased 1,082,796 shares of common stock during the nine-month period at a total cost of $1.0 million.

Guidance, Outlook, and Risks

Outlook and Strategy:

• AZX100: Phase 1a safety study for dermal scarring was completed in May 2008 with a satisfactory safety profile. Phase 1b is planned for completion in Q4 2008, with Phase 2 efficacy studies targeted for Q1 2009.
• Chrysalin: The company has shifted strategy to pursue development partnering or licensing rather than independent clinical trials. Pre-clinical studies in vascular applications are ongoing.
• Capital Resources: Management anticipates cash and short-term investments will be sufficient for the next year, though future funding may be required for new clinical trials or opportunities.

Risks and Contingencies:

• NASDAQ Delisting Risk: The company received notice from NASDAQ that its stock price closed below the $1.00 minimum bid price requirement for over 30 days. Failure to regain compliance could result in delisting, reducing liquidity and increasing volatility.
• Development Risks: As a development-stage company, the firm faces risks related to clinical trial failures, FDA approval delays, and the inability to secure future financing.
• Executive Compensation: In November 2008, the company amended employment agreements for the President and Executive Chairman to increase severance benefits upon termination without cause.

Investor Verification Checklist

• Liquidity Runway: Verify if the current cash and investment balance ($50.9M total) is sufficient to fund the planned Phase 2 trials for AZX100 without additional capital raises.
• NASDAQ Compliance: Monitor the stock price to determine if the company will regain compliance with the $1.00 minimum bid price requirement to avoid delisting.
• Chrysalin Partnership: Assess the likelihood and terms of potential licensing or partnering deals for the Chrysalin platform, given the strategic shift away from independent development.
• Stock Repurchase Impact: Evaluate the impact of the ongoing stock repurchase program on the company's cash reserves and share count.
• Executive Severance: Review the amended employment agreements for the President and Executive Chairman regarding increased severance obligations.